Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by DSMed77on Feb 23, 2020 11:28am

46 Views

Post# 30722669

RE:RE:RE:RE:Patent was granted. Attached is the link

Sammythebull11 wrote:

Sammythebull11 wrote:

Sammythebull11 wrote: PATENT WAS GRANTED!!!

SKL6600 wrote: https://register.epo.org/application?number=EP14791611 click the link. PATENT WAS GRANTED! FACT NOT FICTION!!! This is going to be a great week! Hold tight & Hold Long! Go Kaly Go!!!

FACT!!!!!

Bashers are saying the patent has been withdrawn. The only thing that is going to be withdrawn is all the bashers/shorts here. Good-bye suckas
KLY!!!